Zhejiang Tianyu Pharmaceutical Reports Strong Sales Growth Amid Market Evaluation Shift

Zhejiang Tianyu Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a nuanced view of the company's performance metrics and market position. In the latest quarter ending September 2025, Zhejiang Tianyu reported a notable growth in net sales, reaching CNY 1,527.66 million, which represents a year-on-year increase of 22.92%. This growth is complemented by a significant rise in net profit, which surged by 12.78%. The company has also demonstrated consistent performance, declaring positive results for two consecutive quarters. Key financial indicators show that the company has achieved its highest return on capital employed (ROCE) at 5.29% and an inventory turnover ratio of 1.04 times. Despite a modest annual growth rate in net sales of 3.32% and a decline in operating profit over the past five years, the stock has generated a return of 10.12% over the last year, although this is below the market average of 24.44% for the China Shanghai Composite. Overall, the adjustment in evaluation reflects the company's current standing amidst evolving market dynamics. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.